Group items tagged

In recent NIH Alzeimer's cognitive decline prevention report, it has been observed that Cognitive training identified as protective factor, with highest evidence. Read more at sharpbrains.com

Recent advances in berry supplementation and age-related cognitive decline. Willis LM, Shukitt-Hale B, Joseph JA. Curr Opin Clin Nutr Metab Care. 2009 Jan;12(1):91-4. Review. PMID: 19057194

An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Lilly's drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer's by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer's proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death. The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB). Using that scale, experts said Lilly's findings were roughly on par with Eisai Co Ltd and Biogen Inc's lecanemab, sold under the brand name Leqembi, which reduced cognitive decline by 27% in patients with early Alzheimer's in a study published last year. The results drove Lilly's shares to a record high, up more than 6% at $429.85. Dr. Ronald Petersen, an Alzheimer's researcher at Mayo Clinic, said Lilly's trial is the third to show removing amyloid from the brain slows progression of the disease, which could put to rest some lingering doubts about the benefits of drugs in the class and the amyloid-lowering theory. "It's modest, but I think it's real," he said of the benefit, "and I think it's clinically meaningful." Dr. Erik Musiek, a Washington University neurologist at Barnes-Jewish Hospital, said the efficacy looks as good or better than lecanemab.

For people who spend the majority of their days sitting in standard wheelchairs or lying in beds, pressure sores are a very probable reality. Yet they don't have to be, thanks to assistive technology like tilt or recline wheelchairs that help distribute pressure to other parts of the body. While pressure relief is the main objective to using either a tilt wheelchair or a recline wheelchair, each has its unique qualities that help with posture. (Even though some chairs come with both tilt and recline options, for clarity purposes, they will be addressed as two separate seating systems.) "Obviously, a tilt wheelchair does a better job of providing postural stability by not changing any of the angles of the knee and hip, while recliners allow the pelvis and hips to move through approximately 90 degrees of motion. Both seating systems have their own specific functions," noted David Kreutz, PT, seating specialist at the Shepherd Center in Atlanta. Reclining wheelchairs move the body from a flexed position to an extended position, making the chairs more likely to elicit a spastic response in the user. Because tilt and recline chairs use gravity to their advantage and come with head rests, patients who have poor head, neck and trunk control may benefit from the stability and balance they provide. When in tilt or recline, gravity helps the patient improve balance and head control. Once a tilt chair is prescribed for a patient, it is important to teach the caregivers how to use the tilt function and position the patient correctly. If a patient is cognitively intact, it is also important to teach that individual how he or she should be positioned in the chair, to be able to instruct caregivers. Candidates who would be suited for a recliner chair are those who cannot achieve a 90-degree hip-to-back angle when sitting. For example, patients who have hip precautions following total hip replacement surgery, patients who have had cardiac surgery and might develop

Apple has joined forces with Eli Lilly and Evidation Health on a new feasibility study to detect evidence of brain decline with data from personal digital devices. The research has revealed that these devices may help in the identification of mild cognitive impairment (MCI) and Alzheimer's disease dementia.

Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000 per year. "Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer. Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain swelling and brain bleeding.

Assisted living facilities are for people with cognitive decline or those with trouble managing their daily activities like feeding themselves, getting dressed, or bathing. If your loved one can't perform two or more basic daily activities, they become candidates for assisted living. Choosing an assisted living facility goes beyond just signing up and moving in. The choice should be carefully considered because this is where your loved ones will probably spend the rest of their lives. So, when the time comes, you have to consider pertinent things to help you make the right decisions. Levels Of Care Provided By The Assisted Living Facility Assisted living facilities offer varying levels of care which range from lower levels of care to memory care. Having an idea about the different levels of care provided in assisted living facilities will help you ask the right questions. You should be able to know what level best suits your loved one so that their needs can be addressed adequately. For instance, a person who only needs assistance with mobility but can do other things independently will be suited for level 1 care. On the other hand, those who need additional care because they have difficulty remembering things and can't take care of themselves will be better placed in level 3 care.

Diabetes drugs that also promote weight loss such as Novo Nordisk's Ozempic, becoming a darling of celebrities and investors, are being studied to tackle some of the most difficult-to-treat brain disorders, including Alzheimer's disease. Diabetes regimens, from Ozempic to old mainstays like insulin and metformin, appear to address several different aspects of the metabolic system implicated in Alzheimer's disease, including a protein called amyloid and inflammation, researchers say. The hope is that improving glucose utilisation and tamping down inflammation in the entire body - including the brain - could slow progression of debilitating diseases like Alzheimer's and Parkinson's. Several scientists interviewed by Reuters news agency pointed to mounting research supporting testing diabetes drugs against neurodegenerative diseases. Results are years away and success uncertain. But interest has been buoyed by recent positive data on Alzheimer's drugs developed by Eisai with partner Biogen and by Eli Lilly demonstrating that removing sticky amyloid plaques accumulated in the brain can slow cognition decline caused by the fatal mind-wasting disease. Those successes followed decades of futility that had left many questioning the validity of the amyloid theory behind most experimental Alzheimer's drugs.

Japanese drugmaker Eisai said on Tuesday (January 10) it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease. Nearly all previous experimental drugs using the same approach have failed. The company's application to the European Medicines Agency is based on results from a late-stage study in which the drug was shown to slow down the rate of cognitive decline in patients with early Alzheimer's by 27 per cent, compared with a placebo. Eisai also reiterated its plans to apply for marketing authorization of the drug in Japan by the end of its business year on March 31.